Last week’s hot topic on Pulmonary Hypertension was an article titled PAH Clinical Trial of INOpulse Therapy Shows Benefit, New Phase 3 Study Planned, written by Margarida Azevedo.
This article refers to the recent announcement of the results from the final analysis of the second part of Bellerophon Therapeutics’ Phase 2 clinical trial evaluating INOpulse for the treatment of pulmonary arterial hypertension (PAH), supporting the device’s continued evaluation in an upcoming Phase 3 trial.
The Phase 3 trials are planned to begin this year in Europe and the U.S., using a second-generation INOpulse device, a smaller, lighter and improved version of that used in the now completed studies.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?